Skip to main content
ENDO 2026 Main banner

Diabetes and Vascular Disease

MON-612 - CFTX-2034: A First‑In‑Class SSTR5‑Selective Agonist Antibody for the Treatment of Post‑Bariatric Hypoglycemia

Monday, June 15, 2026
9:00 AM - 2:00 PM CT
Location: ENDOExpo; Poster Floor
Disclosure(s):
Christel Menet, PhD: Confo Therapeutics: Employee (any industry) ()
Post-bariatric hypoglycemia (PBH) is a serious complication of bariatric surgery that can lead to life-threatening hypoglycemic events (impaired cognition, seizures, loss of consciousness), characterized by exaggerated incretins and insulin secretion. Somatostatin receptor subtype 5 (SSTR5) plays a critical role in modulating GI motility, insulin and incretin release, yet no selective agonist targeting this receptor are being developed for this indication.
We describe the discovery and characterization of CFTX-2034, the first agonist monoclonal antibody selective for SSTR5, as a potential therapeutic for PBH.
CFTX-2034 was identified through our proprietary antibody discovery platform using our ConfoBody technology.
CFTX-2034 demonstrated high agonist potency and full selectivity for SSTR5, with no detectable activity on other somatostatin receptor subtypes. In OGTT rodent models, CFTX-2034 significantly reduced insulin, GIPR and GLP1 peaks without triggering basal hyperglycemic level. Pharmacokinetic studies revealed a favorable profile, supporting a projected subcutaneous once-monthly dosing regimen in humans. These findings suggest that CFTX-2034 combines strong efficacy with a practical dosing schedule.
CFTX-2034 represents a first-in-class agonist antibody targeting SSTR5, offering a novel therapeutic approach for PBH. Its unique mechanism of action, robust preclinical efficacy, and long in vivo half-life positions CFTX-2034 as a promising candidate for clinical development.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*